Oncomine Dx Target Test
Life Technologies Corporation · Decision date Mar 4, 2026
What did the FDA approve?
FDA records P160045/S052 as a supplement to PMA P160045, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Mar 4, 2026.
FDA approval order statement
approval for an increase in quality control sampling of components during the QC release process
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Pathology
- Decision date
- Mar 4, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P160045/S052
- Regulatory pathway
- PMA supplement
- Applicant
- Life Technologies Corporation
- Product code
- PQP
- Decision code
- APPR
- Decision date
- Mar 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Life Technologies Corporation
- Product code
- PQP
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P160045/S049 · Related supplement
Oncomine Dx Target Test
P160045/S050 · Related supplement
Oncomine Dx Target Test
P160045/S051 · Related supplement
Oncomine Dx Target Test
P160045/S052 received
Application receipt date recorded by FDA.
P160045/S052 · FDA decision
Special (Immediate Track)
Timeline entries are records held by MedtechLedger for P160045. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160045
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Target TestP160045/S049 | Life Technologies Corporation | PMA supplement | Aug 8, 2025 | FDA |
Oncomine Dx Target TestP160045/S050 | Life Technologies Corporation | PMA supplement | Nov 19, 2025 | FDA |
Oncomine Dx Target TestP160045/S051 | Life Technologies Corporation | PMA supplement | Nov 21, 2025 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Life Technologies Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5781 Van Allen Way, Carlsbad, CA, 92008
Sources and methodology
- Original FDA record: P160045/S052
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



